1 / 2

Immunohistochemistry and New Treatments For Old Diseases

Histone H4 (Acetyl Lys16) antibody<br>

katemeddy04
Download Presentation

Immunohistochemistry and New Treatments For Old Diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Immunohistochemistry is a diagnostic test. It uses antibodies recently marked with a material that could be seen under the microscope. The antibodies are specific to an antigen that quality is able to detect. These antibodies have high affinity with their antigens so the test has high specificity, not actually high sensitivity which will depend on elements. Histone H4 (Acetyl Lys16) antibody It is broadly used to find and classify cancer skin cells Antibodies can be polyclonal or monoclonal. How can this test affect treatment options for a given disease? I will make clear this through an example: Cellular material, cancer or not, have, different antigens (markers) prove membranes, such as pain, glycoproteins, etc. This guns define populations of cellular material like CD4 and CD8 T-lymphocytes and B-lymphocytes (CD-20 + or -). This kind of markers, when they are unique to a specific type of cell, can help not only to differentiate them, but also to target associated with specific antibodies. These antibodies can be used for assessments and also as treatments. I will describe this via an example: A patient comes to any office with a biopsy of his pleura, and it information "Diffuse large B-cell lymphoma". The immunoperoxidase shows CD20 (+) (a B cellular marker) and Bcl-6 (a marker of its beginning from the germinal center). If this patient don't have a CD20 (+) report then he would not be eligible for Rituximab remedy and the diagnosis would be far more somber. Rituximab is a genetically engineered chimeric murine/human monoclonal antibody that finds CD20 receptors that are present in certain B-cell non-Hodgkin lymphomas. Once it reaches its intended goal, it activates other proof cells and the go with system to destroy the b-cell. It is part of the new solutions that are being used in Hemato-oncology.

  2. Before Rituximab, the standard remedy for B-cell lymphoma was CUT therapy. This remedy got a success rate of 40% to 50%. (3-year event-free rate) When Rituximab can be used in conjunction with CHOP chemotherapy, they have shown a success rate up to 99% (when used in early stages).

More Related